She Said We’re Managing It Well. The Word Managing Landed Like A Verdict. Eleven Weeks Until The Next Visit.

The Pulmonology Chair, The Same FEV1 Number, The Word Managing

He sits in the pulmonologist’s chair Thursday afternoon and the spirometer screen has just finished its math. The forced expiratory volume number is in green print at the top right. It is the same number he scored at last spring’s visit, give or take a tenth of a liter.

The doctor turns the monitor toward him so he can see it himself. She says: We are managing this well.

Managing. The word lands somewhere between the second and third rib on the left side.

He knows what she means clinically. Mild COPD on maintenance therapy, no exacerbations since the spring of 2024, peak flow holding steady, no oxygen saturation drops on the six-minute walk. Maintained means he is not getting worse. Maintained is, by any pulmonology textbook measure, what a successful Trelegy plus Spiriva regimen is supposed to deliver in a fifty-seven-year-old with his baseline.

It is also the word he has heard at four consecutive visits.

Eighteen months of the same script. Same two inhalers, same morning dosing, same flat number, same we are managing it well. He folds the visit-summary printout into thirds and slides it into the inside pocket of his jacket on the way to the parking lot. When he gets home he puts it in the kitchen drawer with the others. Four printouts now, stacked underneath a roll of mailing tape, all reading the same thing.

The next appointment is December. Eleven weeks from now. Eleven weeks of the same routine producing, on the printout he already knows is coming, the same number.

The Man Who Walks The Rail-Trail At His Own Pace

The sixty-year-old version of him hikes the rail-trail behind the elementary school every Saturday morning with the dog. Eleven miles round-trip on the maintained gravel. He has a thermos of coffee in the truck for after. The rescue inhaler is in the medicine cabinet at home because he does not bring it on the trail. He has not needed it on the trail in three years.

The FEV1 number on the December printout is up. Not by much. Two-tenths of a liter. The pulmonologist will look at it twice. She will tilt the monitor and ask him what is different. He will tell her about the supplement he started in September. He will hand her the bottle from his coat pocket and ask her to read the panel.

That is the version.

The version he can see when he closes his eyes in the truck after the appointment is over and the heat is on and the windshield wipers are off and the printout in the inside pocket reads something other than maintained.

The sixty-year-old retiree on the rail-trail is three years away. The Trelegy is not getting him there alone. He has eighteen months of evidence that it is doing exactly what it was designed to do, which is to hold the line. Holding the line is not the same as moving the line.

What He Says At The Appointment Versus What He Has Open In The Browser At Home

Out loud in the exam room he says: I trust your plan. I am not one of those guys who self-medicates with internet supplements.

This is true. He has not bought a single thing from a wellness influencer in his life. He has never typed any of the clickbait-medical phrases into a search bar. He shows up to every appointment with a written list of questions.

In private, at the kitchen table on Saturday mornings between coffee and the rail-trail walk, he has seven browser tabs open at any given time. Three of them are PubMed. One is the Decramer 2005 BRONCUS trial summary on the European Respiratory Journal landing page, the one where N-Acetyl-L-Cysteine at 600 mg per day did not change FEV1 decline overall but reduced exacerbation rates in a subgroup of patients not on inhaled corticosteroids. One is the Cazzola 2015 meta-analysis on high-dose NAC and acute COPD exacerbations. One is an r/COPD comment thread from 2024 where a maintenance Trelegy patient described stacking 600 mg NAC and reporting that he was, in his words, not hitting the puffer as much.

The seventh tab is the supplement-facts panel for Mullein & Co. Lung Support Capsules. He has had it open for nine days.

He has not told his pulmonologist any of this. Not because he is hiding it. Because he wants to do the thing first and bring the data, instead of asking the question and getting a no before he has tried it. The portal-message route did not work. He sent one in March asking about NAC. The reply came back five business days later: We do not have a recommendation on NAC supplementation at this time.

That reply is also in the kitchen drawer.

What The Word Managing Quietly Asks Him To Give Up

His daughter texted him in February. She said: Dad you are doing everything right, just follow your doctor’s plan.

She means well. She is also describing a posture, not a strategy.

The word managing, said gently by a competent pulmonologist in a competent appointment, asks the patient to do one specific thing: stop adding. Stop showing up with questions she did not ask. Stop reading the journal abstracts. Stop poking at the regimen. Stop being a participant. Take the inhalers, walk on the treadmill, eat the vegetables, come back in six months for the next maintained reading.

This is, statistically, the correct posture for a mild-COPD patient on a working regimen. He does not dispute the clinical case.

He disputes the identity.

For eighteen months he has been a passenger on his own treatment. The doctor decides. The pharmacy fills. The inhaler does its work or does not. He is the cargo. The maintained number is a verdict that he was on the road and did not crash. It is not a verdict that he was driving.

Adding a supplement to his stack, one he chose, one he can defend with peer-reviewed citations, one he can bring to the December visit in a bottle with the milligrams printed on the label, is not stubbornness and it is not internet-supplement defiance. It is a vote. The only vote he has gotten to cast about his own care since the diagnosis was issued in 2023.

The Trelegy gets a vote. The Spiriva gets a vote. The pulmonologist gets a vote. The supplement-facts panel is the first vote he gets to cast since.

The word managing is not the enemy. The posture managing quietly asks him to adopt is the thing he is no longer willing to keep adopting in silence.

Saturday, 9:40 AM, The Kitchen Table, The Bottle, The Plan

Saturday morning. Coffee mug to the left of the laptop, supplement-facts panel open in tab seven, the amber bottle next to the keyboard. He picks it up and reads the label aloud the way he plans to read it aloud at the pulmonologist’s desk in December.

N-Acetyl-L-Cysteine, 200 milligrams. Mullein Leaf Extract, 300 milligrams. Reishi Mushroom Extract, 100 milligrams. Panax Ginseng Extract, 100 milligrams. Elderberry Extract, 150 milligrams. Vitamin D3, 1000 international units. Other ingredients: Vegetable Capsule, Rice Flour, Magnesium Stearate.

No proprietary blend. No mystery total. No reserved category at the bottom of the panel where the manufacturer hides the amounts.

Here is the plan.

Start Sunday, September 28. Two capsules with the morning coffee, same time he takes the Trelegy. The 200 mg of N-Acetyl-L-Cysteine on the label, plus the 400 mg standalone NAC bottle from Costco he already has in the cupboard, equals 600 milligrams per day, which is the dose range used in the Decramer 2005 trial and the Cazzola 2015 meta-analysis. Total cost of the stack: $36.95 for the Mullein & Co. bottle plus the $14 he already paid for the Costco standalone. Less than one Trelegy copay.

Day one through ninety, log the morning symptoms in the notes app. Three lines a day. Did he wake up clear or did he wake up tight. Did he hit the puffer before noon. Did the afternoon walk produce more or fewer pauses than yesterday. Eight words a line, twenty-four words a day, ninety days. A two-thousand-word file his pulmonologist can read in five minutes at the December visit.

Bring the bottle. Bring the file. Bring the question.

The question is short: Given this dose, this duration, and this self-reported symptom pattern, should we keep the regimen as-is or look at the next FEV1 trend.

That is what being a participant in your own care actually looks like. Not arguing with the doctor. Not deprescribing the inhaler. Not switching to a tea instead of a maintenance bronchodilator. Bringing data she did not have, that she can read on a label that did not hide it, on a timeline that fits her appointment schedule, with a question she can answer yes or no to.